The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.
Mogens Karsboel Boisen
Research Funding - Roche
Christian Dehlendorff
No relevant relationships to disclose
Dorte Linnemann
No relevant relationships to disclose
Jim S. Larsen
No relevant relationships to disclose
Kell Oesterlind
No relevant relationships to disclose
Joergen Hansen
No relevant relationships to disclose
Svend Erik Nielsen
Consultant or Advisory Role - Roche
Per Pfeiffer
Consultant or Advisory Role - Roche
Line Schmidt Tarpgaard
No relevant relationships to disclose
Niels Henrik Hollander
No relevant relationships to disclose
Nina Keldsen
No relevant relationships to disclose
Torben Hansen
No relevant relationships to disclose
Brita Bjerregaard Jensen
No relevant relationships to disclose
Estrid Vilma Solyom Hoegdall
No relevant relationships to disclose
Benny Vittrup Jensen
Consultant or Advisory Role - Roche
Julia S. Johansen
Honoraria - Roche